ANTIBODIES

摘要

Bi-specific antibody molecules having a first binding affinity for a human T-cell receptor capable of activating killing and a second binding affinity for target cells are characterised in that the two heavy chains in the molecule are selected to mitigate the killing of human T-cells by the molecule. Such cytotoxic molecules and fragments thereof retaining the binding affinities of the whole molecule are of value in treating disease, particularly neoplastic, viral and parasitic diseases.